| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 6,493 | 6,691 | 6,973 | 7,260 | 7,622 | 8,164 | 7,869 | 7,805 | 7,050 | 6,319 | 6,845 | 6,727 | 7,014 | 7,339 | 7,198 | 7,850 | 7,326 | 8,472 | 8,150 | 8,159 | 8,180 | 7,640 | 9,019 | 9,124 | 8,575 | 9,822 | 9,780 | 10,247 | 9,500 | 10,646 | 10,894 | 11,274 | 11,099 | 11,990 | 12,297 | 12,407 | 12,419 | 13,057 | 13,618 | 13,903 | 13,429 | 14,251 |
| Expenses | 5,318 | 5,679 | 5,000 | 4,877 | 5,382 | 5,335 | 5,092 | 5,472 | 5,590 | 6,064 | 5,275 | 5,200 | 5,294 | 5,618 | 6,621 | 5,587 | 6,147 | 6,379 | 6,334 | 6,314 | 7,083 | 9,375 | 6,360 | 6,431 | 7,147 | 7,529 | 6,996 | 7,257 | 11,042 | 7,877 | 7,996 | 8,237 | 8,300 | 8,932 | 9,013 | 8,974 | 9,049 | 9,045 | 9,352 | 9,983 | 9,604 | 10,368 |
| EBITDA | 1,175 | 1,012 | 1,973 | 2,383 | 2,240 | 2,829 | 2,776 | 2,333 | 1,460 | 255 | 1,570 | 1,528 | 1,720 | 1,721 | 577 | 2,263 | 1,179 | 2,094 | 1,816 | 1,845 | 1,098 | -1,736 | 2,659 | 2,693 | 1,427 | 2,293 | 2,784 | 2,990 | -1,542 | 2,769 | 2,899 | 3,037 | 2,799 | 3,058 | 3,284 | 3,433 | 3,370 | 4,012 | 4,266 | 3,920 | 3,824 | 3,883 |
| Operating Profit % | 13 % | 13 % | 27 % | 31 % | 27 % | 33 % | 34 % | 29 % | 18 % | 2 % | 20 % | 21 % | 21 % | 21 % | 3 % | 27 % | 13 % | 23 % | 20 % | 21 % | 12 % | -25 % | 25 % | 27 % | 16 % | 22 % | 27 % | 26 % | -18 % | 26 % | 26 % | 26 % | 23 % | 24 % | 25 % | 26 % | 23 % | 28 % | 29 % | 26 % | 25 % | 25 % |
| Depreciation | 462 | 240 | 258 | 251 | 288 | 316 | 304 | 307 | 338 | 347 | 359 | 339 | 455 | 402 | 427 | 471 | 454 | 457 | 473 | 547 | 575 | 496 | 499 | 532 | 554 | 503 | 530 | 554 | 557 | 588 | 610 | 660 | 672 | 651 | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 |
| Interest | 135 | 135 | 158 | 128 | 103 | 135 | 54 | 167 | 45 | 109 | 157 | 95 | 155 | 131 | 130 | 145 | 150 | 104 | 84 | 63 | 52 | 52 | 33 | 26 | 30 | 35 | 36 | 19 | 37 | 14 | 19 | 46 | 93 | 81 | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 |
| Profit Before Tax | 591 | 872 | 1,572 | 2,040 | 2,087 | 2,628 | 2,930 | 2,102 | 1,389 | -159 | 1,114 | 1,148 | 1,376 | 1,274 | 112 | 1,730 | 694 | 1,647 | 1,433 | 1,351 | 577 | -2,184 | 2,206 | 2,163 | 903 | 1,804 | 2,287 | 2,466 | -2,076 | 2,285 | 2,412 | 2,472 | 2,240 | 2,481 | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 |
| Tax | -596 | 115 | 272 | 100 | 424 | 360 | 458 | 380 | 3 | 164 | 113 | 792 | -187 | 88 | 272 | 269 | -26 | 151 | 270 | 332 | 85 | 242 | 263 | 250 | 61 | 400 | 200 | 340 | 152 | 191 | 157 | 291 | 257 | 476 | 406 | 440 | 157 | 563 | 561 | 563 | 1,100 | 880 |
| Net Profit | 1,186 | 757 | 1,299 | 1,940 | 1,663 | 2,268 | 2,471 | 1,722 | 1,386 | -323 | 1,002 | 356 | 1,563 | 1,186 | -160 | 1,461 | 721 | 1,497 | 1,163 | 1,019 | 493 | -2,426 | 1,943 | 1,913 | 842 | 1,404 | 2,086 | 2,126 | -2,227 | 2,093 | 2,256 | 2,181 | 1,983 | 2,006 | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 |
| EPS in ₹ | 3.70 | 2.30 | 4.30 | 6.40 | 5.90 | 8.50 | 9.30 | 6.10 | 5.20 | -1.77 | 3.80 | 1.34 | 5.60 | 4.41 | -1.12 | 5.18 | 2.65 | 5.78 | 4.43 | 3.81 | 1.67 | -6.90 | 7.56 | 7.72 | 3.70 | 6.00 | 8.50 | 8.60 | -9.50 | 8.60 | 9.40 | 9.00 | 8.30 | 8.40 | 9.90 | 10.50 | 11.10 | 11.80 | 12.70 | 12.10 | 9.00 | 9.50 |
Sun Pharmaceutical
Sun Pharmaceutical
1,679.10
+20.10
(1.21%)
Key Fundamentals
Market Cap
3,98,049.70 Cr
EPS
45.60
PE Ratio
38.75
Dividend Yield
0.95 %
Industry
Healthcare 52 Week High
1,923.65
52 Week Low
1,548.00
PB Ratio
5.58
Debt to Equity
0.04
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from36 analysts
Actual
Company News
View All News
The National Company Law Tribunal (NCLT) has approved the merger of Sun Pharmaceutical Medicare and other units with Sun Pharma. The approval allows these subsidiary entities to be consolidated into the main company structure.
Sun Pharma Faces 8-10% Profit Risk from 100% US Tariffs on Patented DrugsSep 28, 2025
The US government imposed a 100% tariff on imported patented drugs starting October 1, which could significantly impact Sun Pharmaceutical Industries. The tariff excludes companies with US manufacturing plants and does not apply to generic medicines. Sun Pharma has substantial exposure with patented drugs accounting for 17% of revenue in FY25, totaling $1,217 million in consolidated sales, with 85-90% coming from the US market. HSBC estimates the tariff could reduce Sun Pharma's earnings by 8-10% in FY26 and FY27 in a worst-case scenario. The company's patented portfolio is expected to grow from 17% of revenue in FY25 to 22% by FY28, with key products including Ilumya, Cequa, Winlevi, and Leqselvi. Sun Pharma currently uses global contract manufacturers, with Ilumya manufactured in South Korea and Europe. The company has over $3 billion in cash as of June 2025, providing flexibility to relocate production to US facilities, though this could take 6-24 months and involve substantial costs. HSBC maintains a 'Buy' rating with a target price of Rs 1,850. Sun Pharma shares closed at Rs 1,585, down 2.6%, and are down 16% year-to-date.
US President Donald Trump announced 100% tariffs on branded and patented drugs imported into the US, effective October 1. The tariffs exempt companies with existing US plants, those building US facilities, or those who have broken ground for construction. Sun Pharma's specialty products including Illumya, Cequa, Odomozo, and Winlevi represent 19.3% of overall sales. The company's specialty sales reached $1.2 billion with 17% growth, while global Illumya sales grew 17% to $681 million. Sun Pharma does not disclose US plant sales figures but management indicated current capacity is sufficient for onshore manufacturing without additional investment. Investment analyst Aditya Khemka from InCred Asset Management noted potential impact on Sun Pharma and Wockhardt, with possible risks for Biocon if biosimilars are included. The Nifty Pharma index declined 2% over the past month, with some pharma stocks falling up to 6%. Sun Pharma shares closed unchanged at ₹1,625, gaining 1.5% over the month.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,679.10 | #1 3,98,049.70 | #7 38.75 | #1 54,729.00 | #6 9.71 | #1 10,980 | #10 -19.84 | 61.71 | |
6,621.50 | 1,75,222.50 | 76.19 | 9,712.00 | 18.67 | 2,191 | 26.74 | 72.60 | |
1,577.60 | 1,26,768.90 | 23.67 | 28,409.50 | 7.12 | 5,291 | 9.88 | 60.63 | |
3,584.30 | 1,19,599.80 | 60.49 | 11,539.40 | 6.99 | 1,911 | 19.91 | 53.74 | |
1,255.90 | 1,03,508.80 | #1 18.25 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.97 | |
2,476.60 | 1,01,344.60 | 53.48 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 47.04 | |
987.65 | 99,073.80 | 21.09 | 23,511.00 | 18.55 | 4,615 | 2.60 | 45.37 | |
1,940.00 | 89,121.90 | 23.79 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.82 | |
5,581.50 | 66,047.70 | 28.61 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.11 | |
1,101.00 | 64,254.10 | 19.04 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.87 |
Growth Rate
Revenue Growth
9.71 %
Net Income Growth
13.80 %
Cash Flow Change
15.96 %
ROE
5.43 %
ROCE
14.46 %
EBITDA Margin (Avg.)
9.26 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 49,028 | 55,530 | 61,410 | 64,516 | 64,694 | 68,253 | 67,667 | 69,808 | 80,744 | 85,500 | 92,101 |
| Fixed Assets | 12,683 | 15,872 | 17,675 | 18,853 | 21,837 | 22,847 | 21,553 | 22,665 | 24,065 | 23,248 | 22,586 |
| Current Assets | 29,122 | 29,941 | 32,954 | 31,636 | 31,069 | 31,654 | 30,442 | 34,865 | 39,862 | 43,433 | 52,594 |
| Capital Work in Progress | 2,039 | 2,175 | 2,801 | 2,465 | 1,411 | 1,220 | 1,567 | 1,287 | 4,973 | 5,354 | 6,644 |
| Investments | 2,117 | 1,830 | 1,192 | 7,143 | 7,903 | 10,143 | 9,612 | 12,849 | 14,824 | 15,026 | 18,354 |
| Other Assets | 32,189 | 35,653 | 39,742 | 36,056 | 33,544 | 34,042 | 34,935 | 33,007 | 36,881 | 41,872 | 44,517 |
| Total Liabilities | 49,028 | 55,530 | 61,410 | 64,516 | 64,694 | 68,253 | 67,667 | 69,808 | 80,744 | 85,500 | 92,101 |
| Current Liabilities | 16,353 | 13,144 | 17,887 | 19,864 | 17,340 | 15,706 | 16,146 | 17,208 | 19,906 | 16,984 | 18,194 |
| Non Current Liabilities | 4,186 | 5,319 | 3,093 | 2,454 | 2,632 | 3,421 | 2,041 | 1,533 | 1,522 | 1,390 | 1,420 |
| Total Equity | 28,489 | 37,068 | 40,431 | 42,198 | 44,723 | 49,125 | 49,480 | 51,066 | 59,316 | 67,126 | 72,486 |
| Reserve & Surplus | 25,383 | 32,741 | 36,400 | 38,074 | 41,169 | 45,025 | 46,223 | 47,771 | 55,755 | 63,427 | 71,978 |
| Share Capital | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 2,927 | 848 | 611 | -736 | -844 | -1,386 | 596 | -1,765 | 116 | 4,662 | 983 |
| Investing Activities | -1,502 | -3,949 | -4,186 | -3,104 | -310 | -2,225 | 407 | -5,556 | -7,220 | -763 | -5,183 |
| Operating Activities | 5,616 | 6,686 | 7,082 | 3,907 | 2,196 | 6,555 | 6,170 | 8,985 | 4,959 | 12,135 | 14,072 |
| Financing Activities | -1,187 | -1,889 | -2,285 | -1,539 | -2,731 | -5,715 | -5,981 | -5,194 | 2,376 | -6,710 | -7,906 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.79 % | 0.00 % | 17.72 % | 17.23 % | 18.02 % | 18.05 % | 17.96 % | 17.26 % |
| DIIs | 21.59 % | 21.93 % | 21.67 % | 20.94 % | 19.94 % | 19.57 % | 18.60 % | 19.14 % | 19.24 % | 19.75 % | 19.67 % | 17.97 % | 18.83 % | 19.28 % | 18.61 % | 18.55 % | 18.70 % | 19.50 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.34 % | 7.21 % | 6.79 % | 6.68 % | 6.49 % | 6.31 % | 5.91 % | 5.76 % | 5.70 % | 5.65 % | 5.56 % | 5.41 % | 5.44 % | 5.57 % | 5.43 % | 5.47 % | 5.42 % | 5.35 % |
| Others | 16.60 % | 16.38 % | 17.05 % | 17.90 % | 19.09 % | 19.64 % | 21.01 % | 20.63 % | 20.58 % | 20.12 % | 3.51 % | 22.13 % | 3.53 % | 3.44 % | 3.46 % | 3.46 % | 3.45 % | 3.42 % |
| No of Share Holders | 0 | 7,09,045 | 7,57,366 | 6,75,908 | 6,80,800 | 6,62,384 | 6,47,167 | 6,43,512 | 6,25,252 | 6,24,561 | 6,16,588 | 6,12,626 | 6,31,392 | 6,73,217 | 6,57,317 | 6,89,623 | 7,04,983 | 7,23,770 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.5 | 2 | 2.75 | 4 | 7.5 | 10 | 11.5 | 13.5 | 16 |
| Dividend Yield (%) | 0.00 | 0.71 | 0.42 | 0.78 | 0.67 | 0.82 | 1.01 | 0.71 | 0.78 | 0.95 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 05 Nov 2025 |  Quarterly Result Announcement | NA | 05 Nov 2025 | 1,668.50 | 1,679.10 |
| 10 Feb 2021 |  Dividend | ₹ 5.50 /share | 09 Feb 2021 | 564.35 | 623.60 |
| 25 Aug 2021 | Dividend | ₹ 2.00 /share | 23 Aug 2021 | 703.80 | 771.35 |
| 10 Feb 2022 | Dividend | ₹ 7.00 /share | 09 Feb 2022 | 827.35 | 886.45 |
| 22 Aug 2022 | Dividend | ₹ 3.00 /share | 19 Aug 2022 | 903.90 | 901.35 |
| 08 Feb 2023 | Dividend | ₹ 7.50 /share | 08 Feb 2023 | 1,050.90 | 1,005.65 |
| 28 Jul 2023 | Dividend | ₹ 4.00 /share | 28 Jul 2023 | 945.00 | 1,134.95 |
| 09 Feb 2024 | Dividend | ₹ 8.50 /share | 09 Feb 2024 | 1,371.60 | 1,500.25 |
| 12 Jul 2024 | Dividend | ₹ 5.00 /share | 12 Jul 2024 | 1,541.15 | 1,583.25 |
| 05 Aug 2024 |  Annual General Meeting | NA | 05 Aug 2024 | 1,520.65 | 1,731.65 |
| 28 Oct 2024 | Quarterly Result Announcement | NA | 28 Oct 2024 | 1,916.85 | 1,860.40 |
| 21 Jan 2025 |  Extraordinary General Meeting | NA | 21 Jan 2025 | 1,806.20 | 1,778.25 |
| 31 Jan 2025 | Quarterly Result Announcement | NA | 31 Jan 2025 | 1,756.85 | 1,739.10 |
| 06 Feb 2025 | Dividend | ₹ 10.50 /share | 06 Feb 2025 | 1,739.10 | 1,753.40 |
| 22 May 2025 | Quarterly Result Announcement | NA | 22 May 2025 | 1,744.85 | 1,731.60 |
| 07 Jul 2025 | Dividend | ₹ 5.50 /share | 07 Jul 2025 | 1,731.60 | 1,676.65 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 1,663.15 | 1,734.95 |
| 31 Jul 2025 | Annual General Meeting | NA | 31 Jul 2025 | 1,731.60 | 1,734.95 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 days ago
3 days agoBoard Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2025.4 days ago
4 days agoESG Overview For FY 2024-254 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Scheme of Arrangement10 days ago
10 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 24, 2025
Sep 24, 2025Closure of Trading WindowSep 22, 2025
Sep 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 18, 2025
Sep 18, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Sep 10, 2025
Sep 10, 2025Update On US FDA Inspection At Sun Pharma Halol FacilitySep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Aug 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Aug 05, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Aug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Rumour verification - Regulation 30(11)Aug 01, 2025
Aug 01, 2025Clarification sought from Sun Pharmaceutical Industries LtdAug 01, 2025
Aug 01, 2025Sun Pharmas Q1FY26 Investor Call Audio RecordingJul 31, 2025
Jul 31, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 31, 2025
Jul 31, 2025Financial Results For The Quarter Ended 30 June 2025Jul 31, 2025
Jul 31, 2025Board Meeting Outcome for Outcome Of The Board MeetingJul 31, 2025
Jul 31, 2025Execution Of Settlement Agreement In The In Re Generic Pharmaceuticals Pricing Antitrust LitigationJul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 21, 2025
Jul 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Jul 19, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 17, 2025
Jul 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 15, 2025
Jul 15, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 14, 2025
Jul 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Jul 14, 2025Sun Pharma Announces Launch Of LEQSELVI™ In The USJul 14, 2025
Jul 14, 2025Sun Pharma Announces Settlement On LEQSELVI™Jul 14, 2025
Jul 14, 2025Board Meeting Intimation for Approval Of Unaudited Financial Results For The Q1 Of FY 2025-26Jul 11, 2025
Jul 11, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 10, 2025
Jul 10, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 04, 2025
Jul 04, 2025Notice For 33Rd Annual General Meeting Of Sun Pharmaceutical Industries LimitedJul 04, 2025
Jul 04, 2025Reg. 34 (1) Annual Report.Jul 04, 2025
Jul 04, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 24, 2025
Jun 24, 2025Update On US FDA Halol InspectionJun 14, 2025
Jun 14, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJun 13, 2025
Jun 13, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 23, 2025
May 23, 2025Investor Audio Call RecordingMay 22, 2025
May 22, 2025Mutual Fund Holdings
ICICI Prudential Equity & Debt Fund Direct-Growth 
SBI Innovative Opportunities Fund Direct-Growth 
Nippon India Large Cap Fund Direct-Growth 
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
Mirae Asset ELSS Tax Saver Fund Direct-Growth 
HDFC Manufacturing Fund Direct - Growth 
Axis Flexi Cap Fund Direct-Growth 
Edelweiss Balanced Advantage Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 56.90
ATR(14)
Less Volatile 27.54
STOCH(9,6)
Overbought 82.17
STOCH RSI(14)
Neutral 76.85
MACD(12,26)
Bullish 3.14
ADX(14)
Weak Trend 11.60
UO(9)
Bearish 56.36
ROC(12)
Uptrend And Accelerating 4.39
WillR(14)
Overbought -13.69
About Sun Pharmaceutical
Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun Pharma has a strong presence in India and the US, which account for about 70% of its revenue. It operates 43 manufacturing facilities worldwide and invests 7-8% of revenue in R&D annually. The company has expanded through acquisitions and licensing deals to strengthen its specialty and generic portfolios. Key specialty products include Ilumya, Winlevi, Cequa and others in dermatology, ophthalmology and oncology. Sun Pharma supplies medicines to over 100 countries and has manufacturing facilities across six continents.
Website
Chairperson NameDilip S Shanghvi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
